top of page
Browse by category
Search


SGLT-2 dapagliflozin plus moderate calorie restriction achieves higher diabetes remission than calorie restriction alone
Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug...


Allurion plans study to optimise muscle mass during GLP-1 therapy in combination with the Allurion Program
Allurion Technologies plans to initiate a clinical study on the combination of the Allurion Program with GLP-1 agonists to improve muscle...


UDCA reduces the need for cholecystectomy in patients with post-LSG gallstones, but ineffective for pre-existing gallstones
Ursodeoxycholic acid (UDCA) is a promising option for reducing the need for cholecystectomy in patients with post-laparoscopic sleeve...


Insurance coverage and type of employment shaping inequities in access to semaglutide
A study by Boston University School of Public Health (BUSPH) researchers has found that disparities in access to semaglutide, with rates...


Journal Watch 22/1/2025
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...


Stent-Over-Sponge as a rescue technique for leak post-bariatric surgery
The Stent-Over-Sponge (SOS) technique is safe and efficacious in dealing with post-operative leaks in patients having undergone bariatric...


STEP UP: Semaglutide 7.2mg achieves 20.7% weight loss and 18.7% regardless of treatment adherence
Novo Nordisk has announced headline results from the STEP UP study, a phase 3b trial in the global STEP programme, which revealed the...


GLP-1ra linked to cognitive benefits but could increase risk of pancreatitis and kidney conditions
Scientists at Washington University School of Medicine (WashU Medicine) in St Louis and the Veterans Affairs (VA) St Louis Health Care...


Positive results for Ascletis’ oral GLP-1ra ASC30
Ascletis Pharma has announced positive topline results from its US single ascending dose (SAD) study of ASC30 oral tablet in patients...


Jiangsu and Kailera report positive topline data for 8mg HRS9531 GLP-1/GIP
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics have announced positive topline data from the 8mg dose of Hengrui Pharma’s Phase...
Browse by tag






bottom of page

